← 返回

Cilta-cel CAR-T 细胞治疗后的惰性 CD4⁺ CAR-T 细胞淋巴瘤

英文原题:Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.

查看英文原题

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.

PubMed 2024/06/13(内容时间) N Engl J Med Q1 · IF 84.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

一名既往接受 ciltacabtagene autoleucel(cilta-cel)CAR-T 细胞疗法治疗骨髓瘤的患者,被诊断出患有累及小肠的惰性 CD4+ 细胞毒性嵌合抗原受体(CAR)T 细胞淋巴瘤。靶向信使 RNA 测序在肿瘤细胞中检测到 CAR 基因产物。对肿瘤和外周血样本进行全基因组测序后,在 SSU72 基因第二内含子中发现单一慢病毒插入位点。此外,在肿瘤样本中还发现了多种可能促成恶性转化的基因改变。(本研究由 MedStar Georgetown University Hospital 资助。)

展开英文摘要原文

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene.

In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.) .

论文信息

作者
Ozdemirli M、Loughney TM、Deniz E、Chahine JJ、Albitar M、Pittaluga S、Sadigh S、Armand P
单位
From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston.United States
文献类型
病例报告
期刊
The New England journal of medicine2024 Jun 13
原文标识
PubMed 38865661 · DOI 10.1056/NEJMoa2401530